Literature DB >> 26463444

Response thresholds for epidemic meningitis in sub-Saharan Africa following the introduction of MenAfriVac®.

Caroline L Trotter1, Laurence Cibrelus2, Katya Fernandez2, Clément Lingani3, Olivier Ronveaux2, James M Stuart4.   

Abstract

BACKGROUND: Since 2010, countries in the African meningitis belt have been introducing a new serogroup A meningococcal conjugate vaccine (MenAfriVac(®)) through mass campaigns. With the subsequent decline in meningitis due to Neisseria meningitidis serogroup A (NmA) and relative increase in meningitis due to other serogroups, mainly N. meningitidis serogroup W (NmW), the World Health Organisation (WHO) initiated a review of the incidence thresholds that guide response to meningitis epidemics in the African meningitis belt.
METHODS: Meningitis surveillance data from African meningitis belt countries from 2002 to 2013 were used to construct a single NmW dataset. The performance of different weekly attack rates, used as thresholds to initiate vaccination response, on preventing further cases was estimated. The cumulative seasonal attack rate used to define an epidemic was also varied.
RESULTS: Considerable variation in effect at different thresholds was observed. In predicting epidemics defined as a seasonal cumulative incidence of 100/10(5) population, an epidemic threshold of 10 cases/10(5) population/week performed well. Based on this same epidemic threshold, with a 6 week interval between crossing the epidemic threshold and population protection from a meningococcal vaccination campaign, an estimated 17 cases per event would be prevented by vaccination. Lowering the threshold increased the number of cases per event potentially prevented, as did shortening the response interval. If the interval was shortened to 4 weeks at the threshold of 10/10(5), the number of cases prevented would increase to 54 per event.
CONCLUSIONS: Accelerating time to vaccination could prevent more cases per event than lowering the threshold. Once the meningitis epidemic threshold is crossed, it is of critical importance that vaccination campaigns, where appropriate, are initiated rapidly.
Copyright © 2015 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Africa; Epidemic thresholds; Meningitis; Meningitis belt

Mesh:

Substances:

Year:  2015        PMID: 26463444     DOI: 10.1016/j.vaccine.2015.09.107

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  9 in total

Review 1.  Vaccine prevention of meningococcal disease in Africa: Major advances, remaining challenges.

Authors:  Mustapha M Mustapha; Lee H Harrison
Journal:  Hum Vaccin Immunother       Date:  2018-01-16       Impact factor: 3.452

2.  Ciprofloxacin for contacts of cases of meningococcal meningitis as an epidemic response: study protocol for a cluster-randomized trial.

Authors:  Matthew E Coldiron; Gabriel Alcoba; Iza Ciglenecki; Matt Hitchings; Ali Djibo; Anne-Laure Page; Celine Langendorf; Rebecca F Grais
Journal:  Trials       Date:  2017-06-24       Impact factor: 2.279

3.  Time delays in the response to the Neisseria meningitidis serogroup C outbreak in Nigeria - 2017.

Authors:  Assad Hassan; G U Mustapha; Bola B Lawal; Aliyu M Na'uzo; Raji Ismail; Eteng Womi-Eteng Oboma; Oyeronke Oyebanji; Jeremiah Agenyi; Chima Thomas; Muhammad Shakir Balogun; Mahmood M Dalhat; Patrick Nguku; Chikwe Ihekweazu
Journal:  PLoS One       Date:  2018-06-19       Impact factor: 3.240

4.  Single-dose oral ciprofloxacin prophylaxis as a response to a meningococcal meningitis epidemic in the African meningitis belt: A 3-arm, open-label, cluster-randomized trial.

Authors:  Matthew E Coldiron; Bachir Assao; Anne-Laure Page; Matt D T Hitchings; Gabriel Alcoba; Iza Ciglenecki; Céline Langendorf; Christopher Mambula; Eric Adehossi; Fati Sidikou; Elhadji Ibrahim Tassiou; Victoire De Lastours; Rebecca F Grais
Journal:  PLoS Med       Date:  2018-06-26       Impact factor: 11.069

5.  Analysis of a meningococcal meningitis outbreak in Niger - potential effectiveness of reactive prophylaxis.

Authors:  Matt D T Hitchings; Matthew E Coldiron; Rebecca F Grais; Marc Lipsitch
Journal:  PLoS Negl Trop Dis       Date:  2019-03-11

6.  Self-enforcing regional vaccination agreements.

Authors:  Petra Klepac; Itamar Megiddo; Bryan T Grenfell; Ramanan Laxminarayan
Journal:  J R Soc Interface       Date:  2016-01       Impact factor: 4.118

7.  [Impact of Controlled Temperature Chain (CTC) approach on immunization coverage achieved during the preventive vaccination campaign against meningitis A using MenAfriVac in Togo in 2014].

Authors:  Dadja Essoya Landoh; Anna-Léa Kahn; Anani Lacle; Kodjovi Adjeoda; Bayaki Saka; Issifou Yaya; Danladi Ibrahim Nassoury; Assima Kalao; Makawa-Sy Makawa; Nsiari-Mueyi Joseph Biey; Andre Bita; Yaovi Temfa Toke; Petit Dörte; Lucile Imboua; Olivier Ronveaux
Journal:  Pan Afr Med J       Date:  2017-05-12

8.  Meningococcal Meningitis Outbreaks in the African Meningitis Belt After Meningococcal Serogroup A Conjugate Vaccine Introduction, 2011-2017.

Authors:  Katya Fernandez; Clément Lingani; Olaolu Moses Aderinola; Kadadé Goumbi; Brice Bicaba; Zewdu Assefa Edea; Clément Glèlè; Badu Sarkodie; Agbeko Tamekloe; Armelle Ngomba; Mamoudou Djingarey; Ado Bwaka; William Perea; Olivier Ronveaux
Journal:  J Infect Dis       Date:  2019-10-31       Impact factor: 5.226

9.  Spatiotemporal Analysis of Serogroup C Meningococcal Meningitis Spread in Niger and Nigeria and Implications for Epidemic Response.

Authors:  Laura V Cooper; Olivier Ronveaux; Katya Fernandez; Clement Lingani; Kadade Goumbi; Chikwe Ihekweazu; Marie-Pierre Preziosi; Antoine Durupt; Caroline L Trotter
Journal:  J Infect Dis       Date:  2019-10-31       Impact factor: 5.226

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.